CD274 and renal carcinoma: Melanoma, non-small-cell lung cancer (NSCLC), and renal cancer have high PD-L1 levels on the tumor cell membrane (cPD-L1), and anti-PD-1 or anti-PD-L1 antibodies have shown effectiveness against these cancers [6].